On this subject, Australian authors Song NK et al. investigated whether biosimilars are as promising as claimed. The authors aimed to compare the efficacy and safety of rituximab biosimilars to reference rituximab in patients with cancer. They cited clinical evidence, including a systematic review of 29 studies of comparing rituximab biosimilars and its reference product, and have found comparability in efficacy and safety which overall adds support of their use in oncology. However, they also noted that there was a knowledge gap in the group of patients who have switched from the originator to biosimilar. 

In the end, the authors recommended further investigation on appropriate biosimilar uptake strategies specifically switching between originators to biosimilars and biosimilars to biosimilars to improve clinician and patient confidence in biosimilar uptake. In Australia, improved uptake of biosimilars have already led to accelerated reduction on immunotherapy costs leading to direct patient savings but also significant savings to the health system leading to wider access to rituximab through the removal of prescribing restrictions to access drug subsidy or reimbursement [1]. 

Conflict of interest 
The authors of the research paper [1] declared that there was no conflict of interest.

Abstracted by Dr Jennifer Ong, Lecturer, Clinical Placement Coordinator, The University of Sydney School of Pharmacy, Faculty of Medicine and Health, Badham, Rm S503, Pharmacy and Bank Building A15, The University of Sydney, NSW 2006 Australia.

Editor’s Comment
Readers interested to learn more about the substitution and interchangeability of biosimilars are invited to visit www.gabi-journal.net to view the following manuscript published in GaBI Journal:

Substitution and interchangeability: time for a conversation?

GaBI Journal is indexed in Embase, Scopus, Emerging Sources Citation Index and more. 

Readers interested in contributing a research or perspective paper to GaBI Journal – an independent, peer reviewed academic journal – please send us your submission here. 

GaBI Journal Citation Impact
2.2 – CiteScore 2021 (calculated on 5 May 2022)
2.4 – CiteScoreTracker 2022 (Last updated on 5 November 2022)

Submit a manuscript to GaBI Journal

Related articles
EMA calls for biosimilar interchangeability across the EU

Canada upholds decision to approve biosimilars where reference product is not marketed

What does the designation of interchangeability for biosimilars in the US mean?

Access to biosimilars for cancer treatments in Latin America

Reference
1. Song NK, Musa H, Soriano M, et al. Safety and efficacy comparisons of rituximab biosimilars to the reference product in patients with cancer: a systematic meta-analysis review. J Pharm Pract Res. 2022. doi:10.1002/jppr.1827

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2022 Pro Pharma Communications International. All Rights Reserved.